生化醫療檢測設備與耗材研發製造 南港國家生技園區
暫不提供
30人
台北市南港區研究院路一段130巷99號C棟3樓
奈捷生物科技(Instant NanoBiosensors),是精準醫療診斷領域的先驅,全球研發總部位於南港國家生技園區,在美國San Francisco設有商務拓展實驗室,荷蘭Utrecht設有歐洲子公司,台灣汐止廠設有ISO 13485/ QMS生產線,在兩大領域展現了本公司在全球的影響力: 在基因檢測領域,我們憑藉著創新的專有檢測設備和試劑,引領「下一代基因檢測革命」。這使醫院能夠實施精準的內部醫療診斷,並根據個人健康管理和治療需求提供快速、準確的診斷報告。 我們的蛋白質檢測部門專注於阿茲海默症血液生物標記檢測的尖端技術,並在此領域取得了重大的國際進展。我們與知名生技公司密切合作,共同開發突破性的阿茲海默症診斷技術。 在歐盟倡議的支持下,以及比爾蓋茲支持的阿茲海默症藥物發現基金會(the Alzheimer's Drug Discovery Foundation) 的資助下,我們正在拓展市值 150 億美元的阿茲海默症檢測市場,提供全球前景並推動醫療保健的可能性。 Instant NanoBiosensors is a pioneer in precision medical diagnostics. With its global R&D headquarters in National Biotechnology Research in Nangang, a business development laboratory in San Francisco, the United States, a European subsidiary in Utrecht, the Netherlands, and an ISO 13485/QMS production line in Xizhi, Taiwan, the company has demonstrated its global influence in two major areas: In the field of genetic testing, we lead the "Next-Generation Genetic Testing Revolution" with our innovative suite of proprietary testing equipment and reagents. This empowers hospitals to implement precise in-house medical diagnostics, delivering swift, accurate diagnostic reports tailored to individual health management and treatment needs. Our protein testing division focuses on cutting-edge technology for blood biomarker detection of Alzheimer's disease, where we have achieved significant international advancements. Collaborating closely with renowned biotechnology firms, we are jointly developing groundbreaking Alzheimer's diagnostics. Supported by initiatives from the European Union and funding from the Alzheimer's Drug Discovery Foundation, backed by Bill Gates, we are spearheading the $15 billion Alzheimer's detection market, offering global prospects and advancing healthcare possibilities. International Media Interview: *2025 年7月數位時代 Business Next Media專訪https://podcasts.apple.com/tw/podcast/ep110-%E5%BE%9E%E5%A5%88%E7%B1%B3%E9%87%91%E5%88%B0%E5%85%A8%E7%90%83%E9%86%AB%E6%9D%90%E5%B8%82%E5%A0%B4-%E5%A5%88%E6%8D%B7%E7%94%9F%E6%8A%80%E7%9A%84%E5%89%B5%E6%96%B0%E8%B7%AF%E5%BE%91-%E5%B0%88%E8%A8%AA%E5%A5%88%E6%8D%B7%E7%94%9F%E6%8A%80%E5%89%B5%E8%BE%A6%E4%BA%BA%E6%9A%A8%E8%91%A3%E4%BA%8B%E9%95%B7-%E9%8D%BE%E5%B0%8A%E6%99%BA-tony/id1684684945?i=1000716613634 *2025 年6月環球生技專訪 https://news.gbimonthly.com/tw/article/show.php?num=77933 https://news.gbimonthly.com/tw/article/show.php?num=77834 *2021 年7月科技部 TTA季刊專訪http://www.instantnano.com/contents/news?id=45 *2020年8月『商業周刊』專訪 https://www.businessweekly.com.tw/Archive/Article?StrId=7002224 *2020年7月環球生技月刊新銳公司專訪 https://www.gbimonthly.com/2020/08/78143/ *2020 年1月 Merck Innovation Center 官網報導 https://reurl.cc/XWKLbM *2020 年1月 Journal Publication in EE Times Asia:Detecting Biomarkers With Optical-Fiber https://www.eetasia.com/news/article/Detecting-Biomarkers-With-Optical-Fiber
A. 基因檢測產品線: 我們的 iNA 嵌入式 NGS 精準醫療系統,包括 iNA 核酸純化系統、iNA NGS 自動化製備工作站和臨床報告系統,提供價格實惠的高品質服務,確保醫院的可持續運作。透過消除傳統外部檢測的高昂成本,我們讓所有癌症患者,無論是否擁有保險,都能享受精準醫療。該系統支持院內精準醫療,提供更快、更準確的診斷報告,並促進個人化的健康管理和治療計畫。未來兩年,我們計劃擴展全球網絡,建立強大的合作夥伴關係,以支持我們的國際擴張和市場策略,進一步鞏固 iNA 的市場地位和全球影響力。 B. 蛋白質檢測產品線: 我們的平台-光感測生物標記分析儀,基於已獲專利的FOPPR(光纖粒子等離子體共振)和IN-Chip(自動流動微流控晶片)技術,擁有超過35項生命科學研究和體外診斷市場的全球專利。該平台使客戶能夠可靠地檢測血液、血清和其他體液中濃度極低(5個數量級)的蛋白質生物標記物,而這些濃度在許多情況下是使用傳統的模擬免疫分析技術無法檢測到的。同時,它也使研究人員能夠定義和驗證僅存在於極低濃度且已透過質譜等技術發現的新型蛋白質生物標記的功能。此業務機會包括共同開發、對外授權和體外診斷(IVD)應用。 A. Gnetic Testing Pipeline: Our iNA Embedded NGS Precision Medicine System, including the iNA Nucleic Acid Purification System, iNANGS Automated Prep Workstation, and clinical reporting system, offers affordable, high-quality services that ensure sustainable hospital operations. By eliminating the high costs of traditional external testing, we make precision medicine accessible to all cancer patients, regardless of insurance coverage. This system enables in-house precision medicine, providing faster and more accurate diagnostic reports, and facilitating personalized health management and treatment plans. Over the next two years, we plan to expand our global network and establish strong partnerships to support our international expansion and market strategy, further strengthening iNA's market position and global influence. B. Protein Testing Pipeline: Our platform , Light Sensing Biomarker Analyzer, based on patented FOPPR (Fiber Optic Particle Plasmon Resonance) and IN-Chip (auto-flowing microfluidic chip) technologies with 35+ global patents for the life science research and in vitro diagnostics markets enables customers to reliably detect protein biomarkers in extremely low concentrations (5 orders) in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allows researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations and have been discovered using technologies such as mass spectrometry. The business opportunity includes co-development, Out-licensing, and IVD applications.
◆ 獎金 / 禮品類 1.年終獎金(依公司營運績效發放) 2.三節禮金 ◆ 保險類 1.勞保 2.健保 ◆ 休閒類 不定期公司聚餐/部門聚餐及年終尾牙 ◆ 制度類 1.員工制服(公司POLO衫) 2.特休...等(提供勞基法規定假別) 3.法規規定之證照課程補助及回訓課程補助 ◆ 補助類 新制6%退職金提撥